Showing 7081-7090 of 7739 results for "".
- Study: Viveve® Improves Vaginal Laxityhttps://practicaldermatology.com/news/study-viveve-improves-vaginal-laxity/2458595/The Viveve System improves vaginal laxity when compared with a sham procedure, a new study suggests. Top-line results from the VIveve Treatment of the Vaginal Introitus to EValuate Efficacy (VIVEVE 1) show that the procedure is both safe and effec
- Oculus Innovative Sciences' Microcyn®-based Lasercyn™ Gel Cleared for Post-procedure Usehttps://practicaldermatology.com/news/oculus-innovative-sciences-microcyn-based-lasercyn-gel-cleared-for-post-procedure-use/2458597/Oculus Innovative Sciences, Inc. has received a new 510(k) clearance from the FDA for the company's new Microcyn®-based Lasercyn™ Gel. Under the supervision of a healthcare professional, Lasercyn Gel is int
- Personalized Medicine In Action: New Biomarker May Pinpoint Aggressive BCChttps://practicaldermatology.com/news/personalized-medicine-in-action-new-biomarker-may-pinpoint-aggressive-bcc/2458598/A biomarker associated with basal cell carcinoma around the eye may help signal which tumors are likely to be aggressive, report researchers from University of Michigan (U-M) at Ann Arbor. The findings, which appear in JAMA Oncology, may help eliminat
- CeraVe® Named Official Skincare Sponsor of LPGA Golf Clinics for Womenhttps://practicaldermatology.com/news/cerave-named-official-skincare-sponsor-of-lpga-golf-clinics-for-women/2458599/CeraVe® skincare products, thave been named Official Skincare Partner of the Ladies Professional Golf Association (LPGA) Golf Clinics for Women, reports Valeant <
- SCCA Doctors Address the Future of Immunotherapy for Melanomahttps://practicaldermatology.com/news/scca-doctors-address-the-future-of-immunotherapy-for-melanoma/2458600/Immunotherapy is the hottest topic in cancer care today, and metastatic melanoma is among the first type to benefit from this fourth cancer therapy. Two Seattle Cancer Care Alliance (SCC
- Checkpoint Inhibitor Shows Promise in MCChttps://practicaldermatology.com/news/checkpoint-inhibitor-shows-promise-in-mcc/2458603/Advanced Merkel cell carcinoma patients who received KEYTRUDA® (pembrolizumab) showed more durable responses than what is typically seen with standard chemotherapy, according to a study presented at the American Association for Cancer Research Annual Meeting 2016 in New Orleans and simul
- Phat Lips: Celebrity Lip Envy Driving Explosive Growth in Lip Enhancementhttps://practicaldermatology.com/news/phat-lips-celebrity-lip-envy-driving-explosive-growth-in-lip-enhancement/2458605/Someone gets their lips enhanced every 19 minutes in the US, the American Society of Plastic Surgeons (ASPS) reports. And a new ASPS survey suggests that celebrity lip envy may be driving this trend. The most likeable lips belong to Jennif
- Recent AAD Meeting Boasts Record Attendancehttps://practicaldermatology.com/news/recent-aad-meeting-boasts-record-attendance/2458607/More than 18,500 people from 107 countries attended the American Academy of Dermatology’s 74th Annual Meeting held in Washington, DC in early March 2016. The meeting featured more than 375 educational sessions, during
- Psoriasis Market Poised for Growth Spurt by 2024https://practicaldermatology.com/news/psoriasis-market-poised-for-growth-spurt-by-2024/2458609/The psoriasis market will more than double to $13.3 billion by 2024 as drugs greatly improve, according to a
- AAD Announces New Officers and Board Membershttps://practicaldermatology.com/news/aad-announces-new-officers-and-board-members/2458608/The American Academy of Dermatology (AAD) announced the results of its annual election. These new officers and board members also will hold the same positions for the American Academy of Dermatology Association. Suzanne Olbricht, MD, FAAD will take the office of Academy president-elect. D